Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®
Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All Cause Emergency Department Visits (-91%, p=0.001), All Cause Office Visits (-41%, p=0.027) and All
View HTML
Toggle Summary Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting
SOLANA BEACH, Calif. , Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.  (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ®  (metoclopramide) nasal spray, announced upcoming poster presentations at
View HTML
Toggle Summary Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors
SOLANA BEACH, Calif. , Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc.  (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ®  (metoclopramide) nasal spray, announced the appointment of Ben Smeal to
View HTML
Toggle Summary Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion
Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16 /share SOLANA BEACH, Calif. , Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI)
View HTML
Toggle Summary Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis SOLANA BEACH, Calif. , Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.  (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with
View HTML
Toggle Summary Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
SOLANA BEACH, Calif. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®  (metoclopramide) nasal spray, announced that management will participate
View HTML
Toggle Summary Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
SOLANA BEACH, Calif. , Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®  (metoclopramide) nasal spray, announced that management will participate
View HTML
Toggle Summary Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills during Q2 75% year-over-year prescription fill increase; 32% growth compared to Q1 2024 Two abstracts
View HTML
Toggle Summary Evoke Pharma, Inc. Supports Gastroparesis Awareness Month
Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif. , Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused
View HTML
Toggle Summary Evoke Pharma, Inc. Announces Reverse Stock Split
SOLANA BEACH, Calif. , July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK) , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that its board of directors
View HTML